Dr Gregory Brammer, OD in Yona, GU - Optometrist

Dr Gregory Brammer, OD is a Optometrist based in Yona, Guam. Dr Gregory Brammer is licensed to practice in Tennessee (license number OD-1054) and his current practice location is 2 Pamela Ct, Baza Gardens, Yona, Guam. He can be reached at his office (for appointments etc.) via phone at (671) 789-0987.

NPI number for Dr Gregory Brammer is 1720073927 and his current mailing address is 2 Pamela Ct, Baza Gardens, Yona, Guam. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1720073927.

Contact Information

	Dr Gregory Brammer, OD
	2 Pamela Ct, Baza Gardens, Yona, GU 96915-4552
	(671) 789-0987
	Not Available

Healthcare Provider's Profile

Full Name	Dr Gregory Brammer
Gender	Male
Speciality	Optometrist
Location	2 Pamela Ct, Yona, Guam
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1720073927
Provider Enumeration Date: 09/13/2005
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dr Gregory Brammer such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1720073927	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
152W00000X	Optometrist	OD-1054 (Tennessee)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Gregory Brammer is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Gregory Brammer, OD 2 Pamela Ct, Baza Gardens, Yona, GU 96915-4552 Ph: (671) 789-0987	Dr Gregory Brammer, OD 2 Pamela Ct, Baza Gardens, Yona, GU 96915-4552 Ph: (671) 789-0987

News Archive

WARFARIN Study initiated to assess utility of genetic testing to reduce warfarin-related adverse events

Iverson Genetic Diagnostics, Inc. announced that the WARFARIN Study was initiated at Colorado Heart & Vascular, P.C. in Denver and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

The Hill: Health law waivers exceed 1,000

The number of temporary waivers granted thus far by the Obama administration reached a total of 1,040 by the end of last week. Meanwhile, regarding another controversial part of the new law, The Hill reports on the possibility of finding alternatives to the individual mandate.

First results from community HIV testing campaign in Uganda

A clinical study in a remote region of southwest Uganda has demonstrated the feasibility of using a health campaign to rapidly test a community for HIV and simultaneously offer prevention and diagnosis for a variety of other diseases in rural and resource-poor settings of sub-Saharan Africa.

Novel therapeutic agent could be effective for treating cancers with certain gene mutations

Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.

NIH's Human Placenta Project aims to revolutionize understanding of the placenta

The National Institutes of Health has announced $46 million in research awards for the Human Placenta Project, an initiative to revolutionize understanding of the placenta. The awards will fund technology development and testing to assess placental function throughout pregnancy, with the ultimate goal of improving pregnancy outcomes and lifelong health.

Dr Gregory Brammer, OD - Optometrist in Yona, GU